Femasys (NASDAQ:FEMY – Get Free Report) posted its quarterly earnings data on Friday. The company reported ($1.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.02), Zacks reports. The company had revenue of $0.33 million for the quarter, compared to analyst estimates of $0.73 million. Femasys had a negative return on equity of 258.08% and a negative net margin of 521.97%.
Femasys Stock Performance
Femasys stock remained flat at $2.29 during midday trading on Friday. 116,831 shares of the company traded hands, compared to its average volume of 170,721. Femasys has a 52-week low of $2.19 and a 52-week high of $22.20. The firm has a market cap of $6.92 million, a PE ratio of -0.42 and a beta of -2.08. The stock’s fifty day moving average price is $3.59 and its 200-day moving average price is $7.31. The company has a debt-to-equity ratio of 0.53, a current ratio of 3.91 and a quick ratio of 1.98.
Insider Buying and Selling
In other Femasys news, CFO Dov Elefant bought 15,625 shares of Femasys stock in a transaction on Friday, August 7th. The shares were bought at an average price of $3.20 per share, for a total transaction of $50,000.00. Following the completion of the transaction, the chief financial officer directly owned 15,625 shares of the company’s stock, valued at $50,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Kathy Lee-Sepsick purchased 15,625 shares of the firm’s stock in a transaction dated Friday, August 7th. The stock was acquired at an average cost of $3.20 per share, for a total transaction of $50,000.00. Following the purchase, the chief executive officer owned 15,625 shares in the company, valued at approximately $50,000. The trade was a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 38,750 shares of company stock worth $124,000 over the last quarter. 7.75% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Analyst Ratings Changes
A number of brokerages have weighed in on FEMY. Wall Street Zen upgraded Femasys to a “hold” rating in a report on Saturday, June 13th. Weiss Ratings upgraded shares of Femasys from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, July 31st. Finally, Maxim Group decreased their price target on shares of Femasys to $10.00 and set a “buy” rating on the stock in a research note on Friday. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Femasys has an average rating of “Moderate Buy” and a consensus price target of $56.67.
Read Our Latest Analysis on Femasys
About Femasys
Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.
The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.
Featured Stories
- Five stocks we like better than Femasys
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Femasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Femasys and related companies with MarketBeat.com's FREE daily email newsletter.
